Lataa...
Are CB2 Receptors a New Target for Schizophrenia Treatment?
Schizophrenia is a complex disorder that involves several neurotransmitters such as dopamine, glutamate, and GABA. More recently, the endocannabinoid system has also been associated with this disorder. Although initially described as present mostly in the periphery, cannabinoid type-2 (CB2) receptor...
Tallennettuna:
| Julkaisussa: | Front Psychiatry |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7673393/ https://ncbi.nlm.nih.gov/pubmed/33329132 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fpsyt.2020.587154 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|